Vimkunya vaccine: a breakthrough in combating chikungunya

The chikungunya virus (CHIKV) is a serious global health concern that is transmitted by Aedes mosquitoes and causes fever, rash, headaches, arthralgia, and fatigue. In 2024, there were approximately 620 000 cases reported and 213 fatalities across the world. In February, Vimkunya (PXVX0317), a virus-like particle vaccine, which is safer than the live-attenuated IXCHIQ vaccine, was approved by the FDA. The Vimkunya has recombinant structural proteins that induce strong neutralizing antibody responses without allowing the virus to replicate. Clinical trials have demonstrated immunogenicity, with a seroresponse rate of ≥87% in older adults and 98% in younger individuals. There were only mild to moderate adverse effects, like headaches, muscle pain, and pain at the injection site, were reported. Vimkunya is a potential approach to lessen the impact of chikungunya and prevent recurrent outbreaks. It has proven to be effective in all age groups, elicits a sustained immune response, and has demonstrated a safer profile in trials. Strategies for fair distribution and ongoing monitoring will be essential for the impact on public health.